Oculis to Present Key Retina Trial Data at Global Congresses

Future presentations at the Ophthalmology Futures Retina Forum, the EURETINA Innovation Spotlight (EIS), the 25th European Society of Retina Specialists (EURETINA) Congress, and the Retina Society Annual Congress have been announced by

UK Launches New CRDC Network to Boost Clinical Research

A UK-wide Commercial Research Delivery Centre (CRDC) Network will be established thanks to a £6.5 million investment from the National Institute for Health and Care Research (NIHR), which was made possible by public-private cooperation

China Approves Hernexeos for Advanced HER2-Mutant Lung Cancer

The National Medical Products Administration (NMPA) of China has authorized Boehringer Ingelheim's Hernexeos (zongertinib tablets) as a monotherapy for the treatment of adult patients with non-small cell lung cancer (NSCLC) that is incurable, locally

India Eyes Russia, Brazil, Netherlands to Diversify Pharma Exports

India is planning to increase pharmaceutical exports to Russia, the Netherlands and Brazil, diversifying its markets beyond the United States, which remains its largest buyer. Two industry sources confirmed the move, highlighting tariff-related uncer

Wegovy Statistically Surpasses Tirzepatide in Cutting Cardiovascular Risks

At the ESC Congress 2025 that took place in Madrid, Novo Nordisk presented findings from the STEER study, which indicated that Wegovy (semaglutide 2.4 mg) provides greater protection to cardiovascular risk than tirzepatide for people living with...

Glenmark to Launch Eribulin Mesylate Injection in US Market

Glenmark Pharmaceuticals has announced its plans to launch Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials, in the United States this September. The product was determined to be bioequivalent and therapeutically equivalent...

Merck's Enlicitide Hits Phase 3 Goals in CORALreef Lipids Trial

Merck announced today positive topline data from its phase 3 CORALreef Lipids trial of enlicitide, an investigational oral PCSK9 inhibitor, in adults with hypercholesterolemia. The once-daily regimen achieved all primary and key secondary...

Baxdrostat Cuts BP Significantly in Hard-to-Control Hypertension

The BaxHTN phase III trial's full results were positive; patients with hard-to-control (uncontrolled and resistant) hypertension who received baxdrostat or placebo in addition to standard of care showed a statistically significant and clinically mean

Novartis Leqvio Shows Strong Results in LDL-C Reduction Study

Novartis reported encouraging findings from V-DIFFERENCE, a phase IV study comparing Leqvio (inclisiran) to a placebo, both of which were given in addition to individually tailored lipid-lowering therapy (LLT), in patients with hypercholesterolemia

Zydus Launches Trivalent Flu Vaccine VaxiFlu in India

In accordance with WHO guidelines, Zydus Lifesciences Ltd., a multinational healthcare organization that leads innovation, announced the introduction of its trivalent influenza (Flu) vaccine, VaxiFlu, for the first time in India. Every year, seasonal

on the deck


Most Viewed

Editor's Guest


© 2025 India Pharma Outlook. All Rights Reserved.